Moreover, major histocompatibility complex-II+ (MHC-II+) ILC3s (CCR6+Lti-like cells) protect against cancer by preventing the development of invasive CRC and resistance to anti-PD-1 immunotherapy in the AOM-DSS CAC model. Here, CCR6 is linked to colorectal carcinoma.